Moderna's stock jumped 6% even as GSK moved its mRNA-based flu vaccine into Phase III trials, signaling strong confidence in mRNA technology beyond direct competition. GSK's vaccine showed promising immune responses in mid-stage trials and targets both haemagglutinin and neuraminidase. The market appears to value the validation of the mRNA platform itself, especially after Moderna's recent success with an mRNA cancer vaccine. Investors should watch for further trial data and how this competitive dynamic affects Moderna's flu vaccine sales and stock performance.
In August, stocks that had been hit by bearish fears, especially in enterprise software, staged a strong comeback. Companies like Moderna surged after positive vaccine news, while Palantir, Veeva, Salesforce, and ServiceNow recovered as concerns abou...
BioNTech halted its Phase 2 trial for a colorectal cancer vaccine after a Data Safety Monitoring Board found no efficacy, causing its stock to fall 8%. This setback also pressured Moderna's shares, which dropped 6%, despite its recent melanoma vaccin...
